Video
Oncotype DX Genomic Prostate Score predicts for long-term clinical outcomes
Author(s):
“This test requires just one millimeter of cancer on a biopsy on five consecutive slides,” says Eric A. Klein, MD.
Video Player is loading.
JCO Precision Oncology recently published the paper, “GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer–Specific Mortality.” In this video, senior author Eric A. Klein, MD, discusses the background behind the study and what impresses him about the Oncotype DX Genomic Prostate Score. Klein is the Chairman of the Glickman Urological & Kidney Institute and a staff member in the Taussig Cancer Institute at Cleveland Clinic.
Related Videos
Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
Ekene Enemchukwu, MD, on the need for better education on GSM, vaginal estrogen
Urologist discusses drug cost savings, price transparency
Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
Expert describes implications of neoadjuvant durvalumab approval in MIBC
Ian Metzler, MD, highlights recent advances in kidney stone technology
Ekene Enemchukwu, MD, on underutilization of vaginal estrogen for GSM
Sima Porten, MD, on gene-environment interactions in bladder cancer development
Naeem Bhojani, MD, expands on key findings from WATER III trial
Hailey Frye discusses improvement of pain management for nephrolithiasis
Related Content
